Real-World Evidence Will Take Center Stage At US FDA Advisory Committee On COVID Boosters
Executive Summary
If regulators agree with Pfizer’s conclusions – and briefing documents suggest that’s a big if – about real-world studies showing Comirnaty’s effectiveness waning over time, thereby justifying the need for a booster dose, it could be part of a historical moment for FDA’s use of RWE.
You may also be interested in...
CDC’s Walensky Suggests Higher Bar May Be Needed For Fourth COVID Vaccine Shots
Pfizer and Moderna have both indicated a fourth mRNA COVID vaccine may be needed. Companies may need to show waning protection against severe disease first.
Placebo Unblinding Process For Pfizer’s COVID Vaccine No Detriment To US FDA Safety Analysis
Despite initial concerns among FDA staff and its advisory committee about unblinding the Comirnaty pivotal trial after emergency authorization, agency’s review of the first COVID vaccine to receive full licensure suggests its safety conclusions were not adversely affected.
From ‘Booster-For-All’ To ‘Pfizer-For-Some’: Lessons From The Third Shot Debate
Biden Administration met its self-declared goal of launching a booster campaign ‘the week of September 20’ – but with a more complex messaging challenge than anyone could have wanted after US FDA authorization and CDC recommendation for a ‘booster’ dose of Pfizer/BioNTech’s COVID vaccine left considerable confusion about who should get a third shot.